Skip to main content
. 2013 Oct;11(8):478–488. doi: 10.1089/adt.2012.498

Fig. 4.

Fig. 4.

Cell-based luciferase refolding assay in cancer cell lines. (A–F) Inhibition of luciferase refolding with novobiocin, 174, 252, 298, 401, and 553 in A549 (■), PC3-MM2 (●), and HCT116 (▲) cancer cell lines using the luciferase refolding assay. The data presented are the mean±SEM of three independent experiments performed in duplicate (n=3). (G) Degradation of client protein AKT and cdc25C in PC3-MM2 cells treated with 252 or 298 and HCT116 cells treated with 553. These results are representative of three independent experiments (n=3).